GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly.
Mette H JensenLaerke Smidt GasbjergKirsa Skov-JeppesenJens C B JacobsenSteen S PoulsenCuiqi ZhouRuta JakubauskaiteFrantz R PoulsenChristian BondeMahmoud AlbaraziBo HalleCharlotte B ChristiansenSamra J SanniSarah BybergBjørn HoeJens J HolstFlemming DelaAase K RasmussenFilip K KnopMai C Arlien-SøborgShlomo MelmedJens Otto L JørgensenMarianne S AndersenBolette HartmannMarianne C KloseUlla Feldt-RasmussenAlexander H Sparre-UlrichMette Marie RosenkildePublished in: The Journal of clinical endocrinology and metabolism (2024)
Of 25 patients with acromegaly, seven had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in four. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist.